Literature DB >> 20443938

Comparative effectiveness research: an approach to avoiding "overgeneralized medicine".

Mark Helfand1, Sergio A Aguilar-Gaxiola, Harry P Selker.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 20443938      PMCID： PMC5350721          DOI： 10.1111/j.1752-8062.2009.00158.x

Source DB:  PubMed          Journal:  Clin Transl Sci        ISSN： 1752-8054            Impact factor:   4.689


× No keyword cloud information.
  4 in total

1.  Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians.

Authors:  Amir Qaseem; Vincenza Snow; J Thomas Cross; Mary Ann Forciea; Robert Hopkins; Paul Shekelle; Alan Adelman; David Mehr; Kenneth Schellhase; Doug Campos-Outcalt; Pasqualina Santaguida; Douglas K Owens
Journal:  Ann Intern Med       Date:  2008-03-04       Impact factor: 25.391

2.  Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group.

Authors:  B R Davis; J A Cutler; D J Gordon; C D Furberg; J T Wright; W C Cushman; R H Grimm; J LaRosa; P K Whelton; H M Perry; M H Alderman; C E Ford; S Oparil; C Francis; M Proschan; S Pressel; H R Black; C M Hawkins
Journal:  Am J Hypertens       Date:  1996-04       Impact factor: 2.689

3.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Authors:  Jeffrey A Lieberman; T Scott Stroup; Joseph P McEvoy; Marvin S Swartz; Robert A Rosenheck; Diana O Perkins; Richard S E Keefe; Sonia M Davis; Clarence E Davis; Barry D Lebowitz; Joanne Severe; John K Hsiao
Journal:  N Engl J Med       Date:  2005-09-19       Impact factor: 91.245

4.  Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

Authors:  Christopher P Cannon; Eugene Braunwald; Carolyn H McCabe; Daniel J Rader; Jean L Rouleau; Rene Belder; Steven V Joyal; Karen A Hill; Marc A Pfeffer; Allan M Skene
Journal:  N Engl J Med       Date:  2004-03-08       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.